Compare Wahed FTSE USA Shariah ETF (HLAL) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Wahed FTSE USA Shariah ETF vs Incyte Corporation — how do they compare? Wahed FTSE USA Shariah ETF trades at $75.91 (market cap $1.00B), while Incyte Corporation trades at $112.79 (market cap $22.85B). The key difference: Incyte Corporation is far larger — about 22.9× Wahed FTSE USA Shariah ETF's market cap, and Wahed FTSE USA Shariah ETF is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Wahed FTSE USA Shariah ETF for 66 Days and Incyte Corporation for 33 Days on average.
| HLAL | INCY | |
|---|---|---|
Market Cap | $1.00B | $22.85B |
Volume | 51,137 | 1,927,029 |
Sector | Sector/Thematic | Health |
52-Week High | $76.54 | $129.93 |
52-Week Low | $57.46 | $83.80 |
Typical Hold Time | 66 Days | 33 Days |
Enterprise Value | — | $18.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HLAL trades at $75.91, down 0.69% today, with a bullish technical signal from moving averages but bearish oscillators. Key financial ratios are unavailable in the provided data, limiting fundamental assessment. A dividend of $0.10 is scheduled for September 2026, indicating a long-term income component. The stock shows mixed signals with strong moving average support but overbought RSI levels.
The outlook is cautiously optimistic due to bullish moving averages, but high RSI suggests near-term pullback risk. Investment opportunity lies in technical strength, while risks include lack of recent fundamental data and potential volatility from overbought conditions. Investors should await updated financials for a clearer picture.
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Wahed FTSE USA Shariah ETF
HLAL is an ETF that invests in Shariah-compliant US companies. It follows a rigorous screening process to exclude businesses involved in non-compliant activities like interest-based finance, alcohol, and gambling.
Read more on HLAL →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
